Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 known ✓ | P08172 | 3/20 | 0.74 |
| ▸ | CHRM1 known ✓ | P11229 | 3/20 | 0.74 |
| ▸ | CHRM3 known ✓ | P20309 | 2/20 | 0.74 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.74 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.74 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.61 |
| ▸ | CHRM4 known ✓ | P08173 | 1/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.61 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.61 |
| ▸ | OPRK1 known ✓ | P41145 | 1/20 | 0.61 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.74 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.74 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.74 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.74 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.74 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.61 |
| ▸ | HRH2 | P25021 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL2528602 | 1.00 | CHRM2 (0.74) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL614300 | 0.91 | CHRM2 (0.68) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL2522817 | 0.91 | CHRM2 (0.68) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| Bromide SCHEMBL2528597 | 0.90 | CHRM2 (0.67) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| Hydrochloric Acid SCHEMBL615546 | 0.90 | CHRM2 (0.67) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| Bromide SCHEMBL2528600 | 0.90 | CHRM2 (0.67) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL2448532 | 0.89 | CHRM2 (0.72) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| Fumaric Acid SCHEMBL1261695 | 0.89 | CHRM2 (0.61) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| Fumaric Acid SCHEMBL1261697 | 0.89 | CHRM2 (0.61) | CHRM2CHRM1CHRM5CHRM3HRH1 | |
| SCHEMBL4859538 | 0.86 | CHRM2 (0.66) | CHRM2CHRM1CHRM5CHRM3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039672-B2 | Method of obtaining 3,3-diphenylpropylamines | INTERQUIM, S.A. (ES) | 2011-10-18 | — | — | US | claimed |
| US-20100286446-A1 | Method of Obtaining 3,3-Diphenylpropylamines | INTERQUIM, S.A. (ES) | 2010-11-11 | — | — | US | claimed |
| EP-1927585-A2 | METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES | Ragactives, S.L. (ES) | 2008-06-04 | — | — | EP | claimed |
| US-20110319666-A1 | METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES | BONDE-LARSEN ANTONIO LORENTE (ES) | 2011-12-29 | — | — | US | disclosed |
| US-8039672-B2 | Method of obtaining 3,3-diphenylpropylamines | INTERQUIM, S.A. (ES) | 2011-10-18 | — | — | US | disclosed |
| US-20100286446-A1 | Method of Obtaining 3,3-Diphenylpropylamines | INTERQUIM, S.A. (ES) | 2010-11-11 | — | — | US | disclosed |
| EP-1927585-A2 | METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES | Ragactives, S.L. (ES) | 2008-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319666-A1 | METHOD OF OBTAINING 3,3-DIPHENYLPROPYLAMINES | CHRM3, CNR2, CHRM2 | CHRM2 3/4885CHRM1 28/4885CHRM3 1/4885 |
| US-20100286446-A1 | Method of Obtaining 3,3-Diphenylpropylamines | CHRM3, HRH4, ADRB3 | CHRM2 4/4885CHRM1 29/4885CHRM3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.